OpGen

OpGen Enterprise Value

The Enterprise Value (EV) of OpGen (OPGN) as of Oct 22, 2026 is 366.54 M USD. In the previous year, Enterprise Value (EV) was 365.23 M USD — a change of 0.36% (higher).

Enterprise Value

366.54 MUSD

YoY

0.36%

Last updated:

Enterprise Value (EV) of OpGen is 2025 366.54 M USD. Enterprise Value (EV) of OpGen was 2024 365.23 M USD. It decreases by 0.36% higher compared to the previous year.

The OpGen Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
362.55 M USD
Jan 1, 2019
367.27 M USD
Jan 1, 2020
374.71 M USD
Jan 1, 2021
354.33 M USD
Jan 1, 2022
372.63 M USD
Jan 1, 2023
377.12 M USD
Jan 1, 2024
365.23 M USD
Jan 1, 2025
366.54 M USD
The OpGen Enterprise Value history
YEAREnterprise ValueYoY
366.54 MUSD+0.36%
365.23 MUSD-3.15%
377.12 MUSD+1.21%
372.63 MUSD+5.16%
354.33 MUSD-5.44%
374.71 MUSD+2.03%
367.27 MUSD+1.30%
362.55 MUSD-0.58%
364.68 MUSD+0.61%
362.46 MUSD+0.95%
359.04 MUSD-2.36%
367.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Enterprise Value (EV) of OpGen is 366.54 M USD in 2025.

Enterprise Value (EV) of OpGen changed from 365.23 M USD to 366.54 M USD, representing a 0.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) OpGen since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OpGen

All Key Metrics — OpGen